{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:23:31Z","timestamp":1788967411916,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.08.010","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:26:35Z","timestamp":1787181995000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cutaneous Toxicities of T-Cell\u2013Redirecting Therapies in Multiple Myeloma: An EADV Task Force Position Paper and Practical Recommendations"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-9152","authenticated-orcid":false,"given":"Vasiliki","family":"Nikolaou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Koumaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-1229","authenticated-orcid":false,"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.clml.2026.08.010_bib0001","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2026.08.010_bib0002","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.08.010_bib0003","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-025-01334-5","article-title":"Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma","volume":"15","author":"Golmohammadi","year":"2025","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2026.08.010_bib0004","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/j.clml.2025.09.012","article-title":"Dermatologic adverse events following CD19-directed CAR T-cell therapy in hematologic malignancies","volume":"26","author":"Storgard","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2026.08.010_bib0005","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S2352-3026(25)00035-3","article-title":"Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era","volume":"12","author":"Major","year":"2025","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2026.08.010_bib0006","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"28","key":"10.1016\/j.clml.2026.08.010_bib0007","doi-asserted-by":"crossref","first-page":"19874","DOI":"10.1074\/jbc.274.28.19874","article-title":"The catalog of human hair keratins. I. Expression of the nine type I members in the hair follicle","volume":"274","author":"Langbein","year":"1999","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.clml.2026.08.010_bib0008","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.jid.2022.06.022","article-title":"Comparative spatial transcriptomic and single-cell analyses of Human nail units and hair follicles show transcriptional similarities between the onychodermis and follicular dermal papilla","volume":"142","author":"Shim","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.clml.2026.08.010_bib0009","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00262-025-04036-w","article-title":"Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity","volume":"74","author":"Nakamura","year":"2025","journal-title":"Cancer Immunol Immunother"},{"issue":"508","key":"10.1016\/j.clml.2026.08.010_bib0010","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax8861","article-title":"CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.clml.2026.08.010_bib0011","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1210\/en.2011-1504","article-title":"B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies","volume":"153","author":"Alexaki","year":"2012","journal-title":"Endocrinology"},{"issue":"10301","key":"10.1016\/j.clml.2026.08.010_bib0012","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.clml.2026.08.010_bib0013","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.clml.2026.08.010_bib0014","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.clml.2026.08.010_bib0015","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","article-title":"Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial","volume":"11","author":"Zhou","year":"2024","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.clml.2026.08.010_bib0016","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2352-3026(25)00176-0","article-title":"GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial","volume":"12","author":"Jin","year":"2025","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.08.010_bib0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.clml.2026.08.010_bib0018","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1080\/14712598.2025.2595122","article-title":"Talquetamab for the treatment of relapsed\/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence","volume":"25","author":"Moore","year":"2025","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.clml.2026.08.010_bib0019","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s12185-025-04134-6","article-title":"Talquetamab in Japanese patients with relapsed\/refractory multiple myeloma in the MonumenTAL-1 study","volume":"123","author":"Ito","year":"2026","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2026.08.010_bib0020","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jaad.2023.08.094","article-title":"Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab","volume":"90","author":"Lery","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.clml.2026.08.010_bib0021","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","article-title":"Clinical management of patients with relapsed\/refractory multiple myeloma treated with Talquetamab","volume":"24","author":"Chari","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.clml.2026.08.010_bib0022","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/ddg.15502","article-title":"Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review","volume":"22","author":"Mansilla-Polo","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"issue":"8","key":"10.1016\/j.clml.2026.08.010_bib0023","doi-asserted-by":"crossref","first-page":"828","DOI":"10.36849\/jdd.7170","article-title":"Talquetamab-induced Grover's disease","volume":"22","author":"Kresch","year":"2023","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.clml.2026.08.010_bib0024","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2026.08.010_bib0025","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.25251\/skin.7.5.14","article-title":"Alopecia areata: hair and nail findings in a patient undergoing talquetamab therapy for multiple myeloma","volume":"7","author":"Jiminez","year":"2023","journal-title":"SKIN J Cutaneous Med"},{"issue":"22","key":"10.1016\/j.clml.2026.08.010_bib0026","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.08.010_bib0027","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 magnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.08.010_bib0028","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jdcr.2024.10.013","article-title":"Injection site reaction to teclistamab in a patient with multiple myeloma","volume":"56","author":"Yoon","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.clml.2026.08.010_bib0029","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ajh.70130","article-title":"Dermatologic adverse effects with elranatamab mimicking talquetamab","volume":"101","author":"Hammami","year":"2026","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.clml.2026.08.010_bib0030","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1007\/s00277-025-06524-6","article-title":"Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed\/refractory multiple myeloma: a meta-analysis of interventional and real-world studies","volume":"104","author":"Techaapornkun","year":"2025","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.clml.2026.08.010_bib0031","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clml.2026.08.010_bib0032","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.clml.2025.10.024","article-title":"Preemptive immunoglobulin prophylaxis reduces infections in patients treated with anti-BCMA bispecific antibodies","volume":"26","author":"Piron","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2026.08.010_bib0033","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-026-01471-5","article-title":"Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies","volume":"16","author":"Umyarova","year":"2026","journal-title":"Blood Cancer J"},{"issue":"25","key":"10.1016\/j.clml.2026.08.010_bib0034","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.08.010_bib0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.08.010_bib0036","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","article-title":"T cell malignancies after CAR T\u2009cell therapy in the DESCAR-T registry","volume":"31","author":"Dulery","year":"2025","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.clml.2026.08.010_bib0037","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1056\/NEJMe2405538","article-title":"T-cell cancer after CAR T-cell therapy","volume":"390","author":"Mitchell","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2026.08.010_bib0038","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.clml.2026.08.010_bib0039","doi-asserted-by":"crossref","first-page":"2","DOI":"10.7861\/clinmed.2022-0335","article-title":"Skin of colour: essentials for the non-dermatologist","volume":"23","author":"Hutchison","year":"2023","journal-title":"Clin Med (Lond)"},{"issue":"2","key":"10.1016\/j.clml.2026.08.010_bib0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/jdv.70040","article-title":"Nail toxicities associated with cancer therapies: insights and recommendations from the EADV task force dermatology for cancer patients","volume":"40","author":"Iorizzo","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.clml.2026.08.010_bib0041","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamadermatol.2023.3003","article-title":"Cutaneous adverse events and cancer survival prognosis with immune checkpoint inhibitor treatment: a systematic review and meta-analysis","volume":"159","author":"Du","year":"2023","journal-title":"JAMA Dermatol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:57:24Z","timestamp":1788965844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"alternative-id":["S2152265026002715"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.08.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous Toxicities of T-Cell\u2013Redirecting Therapies in Multiple Myeloma: An EADV Task Force Position Paper and Practical Recommendations","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}